Список литературы

1. Sharpe R.M., Skakkebaek N.E. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 1993; 341: 1392 - 5.

2. Garner M.J., Turner M.C., Ghadirian P., Krewski D. Epidemiology of testicular cancer: an overview. Int J Cancer 2005; 116: 331 - 9.

3. Chieffi P., Franco R., Portella G. Molecular and cell biology of testicular germ cell tumors. Int Rev Cell Mol Biol 2009; 278: 277 - 308.

4. Hemminki K., Chen B. Familial risks in testicular cancer as aetiological clues. Int J Androl 2006; 29(1): 205 - 10.

5. Looijenga L.H., de Munnik H., Oosterhuis J.W. A molecular model for the development of germ cell cancer. Int J Cancer 1999; 83: 809 - 14.

6. Grigor K.M., Skakkebaek N.E. Pathogenesis and cell biology of germ cell neoplasia: general discussion. Eur Urol 1993; 23: 46 - 53.

7. Ferlay J., Colombet M., Soerjomataram I. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356 - 87.

8. WHO classification of tumours of the urinary system and male genital organs. Ed. by H. Moch et al. Lyon: IARC, 2016.

9. Testis. In: TNM classification of malignant tumours (8th ed.). Ed. by J.D. Brierley, M.K. Gospodarowicz, C. Wittekind. Oxford: Wiley-Blackwell, 2017.

10. International Germ Cell Consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594 - 603.

11. Oldenburg J., S.D., Nuver J. et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol 2018; 29(8): 1658 - 86.

12. Трякин А.А., Гладков О.А., Матвеев В.Б., с соавт. Практические рекомендации по лекарственному лечению герминогенных опухолей у мужчин//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-33.pdf.

13. Gilligan T., Lin D.W., Aggarwal R., et al. NCCN Clinical Practice Guidelines in Oncology (NCCN ). Testicular Cancer. Version 1.2020 - October 9, 2019. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf.

14. International Collaboration On Cancer Reporting (ICCR). Neoplasia of the testis - orchidectomy histopathology reporting guide. Available at: http://www.iccr-cancer.org/getattachment/Datasets/Published-Datasets/Urinary-Male-Genital/Neoplasia-of-the-Testis-Orchidectomy-TNM8/Testis-Orchidectomy-bookmarked-1st-edition-FINAL-FOR-PUBLICATION.pdf.

15. Tsili A.C., Sofikitis N., Stiliara E., Argyropoulou M.I. MRI of testicular malignancies. Abdom Radiol (NY) 2019; 44(3): 1070 - 82.

16. Hale G.R., Teplitsky S., Truong H. Lymph node imaging in testicular cancer. Transl Androl Urol 2018; 7(5): 864 - 74.

17. Трякин А.А., Федянин М.Ю., Буланов А.А. и др. Метастазы герминогенных опухолей в головной мозг. Опыт Российского онкологического центра. Онкоурология 2013; (4): 59 - 71.

18. Albers P., A., Bierhoff E. et al. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. Urology 1999; 54: 714 - 8.

19. Tabernero J., Paz-Ares L., Salazar R. et al. Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol 2004; 171: 164 - 7.

20. Kollmannsberger C., Tandstad T., Bedard P. et al. Characterization of relapse in patients with clinical stage I (CSI) nonseminoma (NS-TC) managed with active surveillance (AS): a large multicenter study. J Clin Oncol 2013; (suppl): 4503.

21. De Wit R., Roberts J.T., Wilkinson P.M. et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized trial of EORTC and MRC. J Clin Oncol 2001; 19(6): 1629 - 40.

22. Mead G.M., Cullen M.H., Huddart R. et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with meta-static germ cell cancer: a medical research council trial. Br J Cancer 2005; 93: 178 - 84.

23. Loehrer P.J., Gonin R., Nichols C.R. et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500 - 4.

24. De Wit R., Stoter G., Sleijfer D.T. et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998; 78: 828 - 32.

25. Kollmannsberger C., Beyer J., Liersch R. et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22: 108 - 14.

26. Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germcell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008; 19: 448 - 53.

27. Feldman D.R., Sheinfeld J., Bajorin D.F. et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28(10): 1706 - 13. Erratum in: J Clin Oncol 2010; 28(34): 5126.

28. Hoei-Hansen C.E., Rajpert-De Meyts E., Daugaard G., Skakkebaek N.E. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 2005; 16: 863 - 8.

29. Petersen P.M., Giwercman A., Daugaard G. et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 2002; 20: 1537 - 43.

30. Heidenreich A., W., Albrecht W. et al. Testis-preserving surgery in bilateral testicular germ cell tumours. Br J Urol 1997; 79: 253 - 7.

31. Трякин А.А. Лекарственное и комбинированное лечение несеминомных герминогенных опухолей у мужчин. Дис. ... д-ра мед. наук. М., 2015. 254 с.

32. Cohn-Cedermark G., Stahl O., Tandstad T. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Andrology 2015; 3: 102 - 10.

33. Albers P. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I NSGCT:. AUO trial AH 01/94 by the German Testicular Cancer Study. J Clin Oncol 2008; 26(18): 2966 - 72.

34. Fedyanin M, Tryakin A, Bulanov A, et al. Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors. J Cancer Res Clin Oncol. 2015 Jul; 141(7): 1259 - 64.

35. Tran B., Ruiz-Morales J.M., Billalabeitia E.G. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). Cancer Med. 2019 Nov 12. doi: 10.1002/cam4.2674. [Epub ahead of print].

36. Tryakin A, Fedyanin M, Bulanov A, et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol. 2018 Sep; 144(9): 1817 - 1823.

37. Feldman D.R., Lorch A., Kramar A. et al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options - an analysis from the Global Germ Cell Cancer Group. J Clin Oncol 2016; 34(4): 345 - 51.

38. Daneshmand S., Albers P., Fossa S.D. et al. Contemporary management of postchemotherapy testis cancer. EurUrol 2012; 62: 867 - 76.

39. Tryakin A., Fedyanin M., Mitin A. et al. Complete disappearance of retroperitoneal lymph nodes after induction chemotherapy in advanced nonseminomatous germ cell tumors (NSGCT): is there a place for adjunctive surgery? J Clin Oncol 2012; 30(15 suppl).

40. Kollmannsberger C. et. al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 2010; 28: 537.

41. De Santis M., Becherer A., Bokemeyer C. et al. 2-18Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22: 1034 - 9.

42. Cathomas R., Klingbiel D., Bernard B. et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol 2018; 4: JCO1800210.

43. Motzer R.J., Sheinfeld J., Mazumdar M. et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000; 18(12): 2413 - 8.

44. Mead G.M., Cullen M.H., Huddart R. et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005; 93: 178 - 84.

45. Loehrer P.J., Gonin R., Nichols C.R. et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500 - 4.

46. Donadio A.C., Motzer R.J., Bajorin D.F. et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 2003; 21(23): 4285 - 91.

47. S., Daneshmand. Role of surgical resection for refractory germ cell tumors. Urol Oncol 2015;33(8):370-8.

48. Владимирова Л.Ю., Гладков О.А., Когония Л.М., Королева И.А., Семиглазова Т.Ю. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 502 - 511. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-35.pdf.

49. Манзюк Л.В., Багрова С.Г., Копп М.В., Кутукова С.И., Семиглазова Т.Ю. Использование остеомодифицирующих агентов для профилактики и лечения патологии костной ткани при злокачественных новообразованиях//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 512 - 520. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-36.pdf.

50. Сакаева Д.Д., Орлова Р.В., Шабаева М.М. Практические рекомендации по лечению инфекционных осложнений фебрильной нейтропении и назначению колониестимулирующих факторов у онкологических больных//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 521 - 530. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-37.pdf.

51. Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Клинические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой терапией//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 531 - 544. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-38.pdf.

52. Виценя М.В., Агеев Ф.Т., Гиляров М.Ю., с соавт. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 545 - 563.

53. Королева И.А., Болотина Л.В., Гладков О.А., с соавт. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 564 - 574. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-40.pdf.

54. Сытов А.В., Лейдерман И.Н., Ломидзе С.В., с соавт. Практические рекомендации по нутритивной поддержке онкологических больных//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 575 - 583. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-41.pdf.

55. Громова Е.Г., Бирюкова Л.С., Джумабаева Б.Т., Курмуков И.А. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 591 - 603. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-44.pdf.

56. Сомонова О.В., Антух Э.А., Елизарова А.Л., с соавт. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 604 - 609. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-45.pdf.

57. Буйденок Ю.В. Рекомендации по лечению последствий экстравазации противоопухолевых препаратов//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 610 - 616. https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-46.pdf.

58. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013; 92(8): 715 - 27.

59. Nilsson H., Angeras U., Bock D. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016; 6(1): e007997.

60. Hulzebos E.H., Helders P.J., Favie N.J. et al. Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery: a randomized clinical trial. JAMA 2006; 296(15): 1851 - 7.

61. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Ann Surg Oncol 2015; 22(13): 4117 - 23.

62. Swarm R., Abernethy A.P., Anghelescu D.L. et al. Adult cancer pain. J Natl Compr Canc Netw 2010; 8: 1046 - 86.

63. Azhar R.A., Bochner B., Catto J. et al. Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs. Eur Urol 2016; 70(1): 176 - 87.

64. Nilsson H., Angeras U., Bock D. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016; 6(1): e007997.

65. Shin K.Y., Guo Y., Konzen B. et al. Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011; 90(5): 63 - 8.

66. Shehadeh A., El Dahleh M., Salem A. et al. Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients" outcome. Hematol Oncol Stem Cell Ther 2013; 6(3-4): 105 - 11.

67. Fallon M., Giusti R., Aielli F. et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29(Suppl 4): iv166 - 91.

68. Cox C.L., Montgomery M., Oeffinger K.C. et al. Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. Cancer 2009; 115(3): 642 - 54.

69. Musculoskeletal Cancer Surgery. Ed. by M. Malawer. Dordrecht: Springer, 2013. Pp. 583 - 593.

70. Committee NMA: The diagnosis and treatment of lymphedema. Position Statement of the National Lymphedema Network. 2011. 19 p.

71. Segal R., Zwaal C., Green E. et al. Exercise for People with Cancer Guideline Development G: Exercise for people with cancer: a systematic review. Curr Oncol 2017; 24(4): e290 - 315.

72. Boyd C., Crawford C., Paat C.F. et al. Evidence for Massage Therapy Working G: The impact of massage therapy on function in pain populations - a systematic review and meta-analysis of randomized controlled trials: Part II, Cancer pain populations. Pain Med 2016; 17(8): 1553 - 68.

73. Stout N.L., Baima J., Swisher A.K. et al. A systematic review of exercise systematic reviews in the cancer literature (2005 - 2017). PM R 2017; 9(9S2): S347 - 84.

74. Hu M., Lin W. Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol 2012, 127(3): 156 - 64.

75. Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3(7): 961 - 8.

76. Kinkead B., Schettler P.J., Larson E.R. et al. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer 2018; 124(3): 546 - 54.

77. Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44(9): 1289 - 304.

78. Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018; 26(4): 1019 - 28.

79. Lee J.M., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012; 30(15 suppl): 9019.

80. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2017; 38(2): 85 - 94.

81. Kilinc M., Livanelioglu A., Yildirim S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014; 46(5): 454 - 60.

82. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014; 9(9): e107418.

83. Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018; 10(Suppl35): S4391 - 9.

84. Ross M., Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017; 21(2): 226 - 33.

85. Rief H., Omlor G., Akbar M. et al. Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer 2014; 14: 6.

86. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg 2015; 33(10): 487 - 91.

87. Temoshok L. Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response. Soc Sci Med 1985; 20(8): 833 - 40.

88. S.R., Dirksen. Perceived well-being in malignant melanoma survivors. Oncol Nurs Forum 1989; 16(3): 353 - 8.

89. Lichtenthal W.G., Cruess D.G., Schuchter L.M., Ming M.E. Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma. J Health Psychol 2003; 8(6): 705 - 19.

90. Sollner W., Zschocke I., Zingg-Schir M. et al. Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics 1999; 40(3): 239 - 50.

91. Devine D., Parker P.A., Fouladi R.T., Cohen L. The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 2003; 12(5): 453 - 62.

92. Chovanec M., Abu Zaid M., Hanna N. et al. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol 2017; 28(11): 2670 - 9.